Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Intercept Withdraws Ocaliva from US Market Amid Regulatory Challenges

Intercept Pharmaceuticals has announced the withdrawal of its liver disease drug Ocaliva (obeticholic acid) from the US market, marking the end of a tumultuous journey for the once-promising treatment. This decision comes in response to a request from the US Food and Drug Administration (FDA) and follows a series of regulatory setbacks for the company.

NoahAI News9/13/2025

Eli Lilly Pauses UK Biotech Incubator Plans Amid Industry Concerns

Pharmaceutical giant Eli Lilly has hit the pause button on its plans to establish a Gateway Labs site in the United Kingdom, citing uncertainties in the country's life sciences landscape. This decision comes as part of a broader reassessment of the company's £279 million investment commitment to the UK's biotech sector.

NoahAI News9/13/2025

Philips and Masimo Renew and Expand Patient Monitoring Partnership

Philips and Masimo have announced a renewed multi-year strategic collaboration, focusing on the integration of patient monitoring technologies and the development of new tools, including artificial intelligence algorithms. This partnership extension comes as both companies aim to improve patient care through advanced monitoring solutions.

NoahAI News9/13/2025

Galimedix's Oral Alzheimer's Drug Shows Promise in Phase 1 Trial

Maryland-based biotech company Galimedix Therapeutics has announced positive results from the phase 1 clinical trial of its oral Alzheimer's disease candidate, GAL-101. The small molecule drug successfully crossed the blood-brain barrier and demonstrated a favorable safety profile, paving the way for further development and potential fundraising for phase 2 studies.

NoahAI News9/13/2025

Pharmaceutical Industry Update: Executive Moves, Clinical Advances, and Legal Challenges

Takeda Pharmaceutical has announced a significant addition to its executive team. Rhonda Pacheco, formerly of Eli Lilly, will assume the role of head of Takeda's U.S. business unit on September 29. Pacheco brings over a decade of experience from Lilly, where she most recently served as group vice president of the cardiometabolic health unit. Her tenure at Lilly was marked by successful launches of GLP-1 drugs, positioning her as a valuable asset for Takeda's future endeavors.

NoahAI News9/13/2025

GLP-1 Drugs Show Promise in Cancer Treatment and Prevention

Glucagon-like peptide-1 (GLP-1) receptor agonists, widely known for their efficacy in treating diabetes and obesity, are now emerging as potential game-changers in cancer care. Recent research suggests these drugs may have far-reaching effects beyond weight loss, potentially impacting cancer risk, treatment outcomes, and even drug resistance.

NoahAI News9/13/2025

CVS Health Announces Leadership Changes in Care Delivery Business

CVS Health, a major player in the healthcare industry, has made significant changes to its care delivery leadership, signaling a strategic shift in its retail health and home health businesses. These moves come as the company continues to integrate its recent acquisitions and streamline operations across its diverse healthcare portfolio.

NoahAI News9/13/2025

AI Drives Investment and Acquisitions in Medical Technology Sector

Artificial intelligence (AI) is emerging as a key driver of investment and acquisition activity in the medical technology sector in 2025, with AI-focused companies attracting significant funding and becoming prime targets for mergers and acquisitions.

NoahAI News9/13/2025

AstraZeneca Pauses UK Expansion as Pharma Giants Reconsider British Investments

In a week marked by significant shifts in the pharmaceutical landscape, AstraZeneca has become the latest industry giant to pause its expansion plans in the United Kingdom. This decision comes amid a growing trend of major pharmaceutical companies reevaluating their presence in Britain, citing concerns over the country's investment climate and valuation of innovative medicines.

NoahAI News9/13/2025

Neuroscience Biotech LB Pharma Breaks IPO Drought with Upsized $285M Offering

LB Pharma has successfully broken the biotech IPO stalemate, making its debut on the Nasdaq in an upsized $285 million offering. The neuroscience-focused company's initial public offering marks the end of a seven-month period during which no biotech had gone public.

NoahAI News9/12/2025

Pharmaceutical Industry Faces Widespread Layoffs and Strategic Shifts Amid Market Pressures

The pharmaceutical and biotech sectors are experiencing significant upheaval as companies across the industry announce major workforce reductions and strategic realignments. This wave of restructuring comes as firms grapple with challenging market conditions, pipeline setbacks, and the need to optimize resources for future growth.

NoahAI News9/12/2025

Biopharma Job Market Faces Challenges as Layoffs Continue and Openings Decline

The pharmaceutical and biotechnology industry is grappling with a tightening job market, as recent data reveals a significant decrease in job openings and a wave of layoffs affecting thousands of professionals. This trend is reshaping the employment landscape for biopharma workers and raising concerns about the sector's near-term growth prospects.

NoahAI News9/12/2025

«1...59 60 61...67 »